北京大成（海口）律师事务所 关于海南海药股份有限公司2026年第一次临时股东会的 法 律 意 见 书 大成 is Dentons' Preferred Law Firm in China. 北京大成（海口）律师事务所 1 北京大成（海口）律师事务所 关于海南海药股份有限公司2026年第一次临时股东会的 法律意见书 致：海南海药股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民 共和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市 公司股东会规则》（以下简称"《股东会规则》"）等法律、法规和规范性文件的 要求，北京大成（海口）律师事务所（以下简称"本所"）接受海南海药股份有限 公司（以下简称"公司"）的委托，指派律师参加公司2026年第一次临时股东会 （以下简称"本次股东会"）。 本所声明：本所律师仅对本次股东会的召集、召开程序、出席会议人员资格、 召集人资格、表决程序、表决结果发表法律意见，并不对本次股东会所审议的议 案、议案所涉及的事项及内容发表意见。本所律师同意将本法律意见书随本次 股东会其他信息披露资料一并公告。 本法律意见书仅供见证公司本次股东会相关事项 ...

证券代码：000566 证券简称：海南海药 公告编号：2026-013 海南海药股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、特别提示： 1、本次股东会无否决议案的情形； 2、本次股东会不涉及变更前次股东会决议的情形。 二、会议召开的情况 1、会议召开的日期、时间： （1）现场会议时间：2026 年 03 月 13 日 15:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为2026年03 月13日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投 票的具体时间为2026年03月13日9:15至15:00的任意时间。 2、召开地点：海南省海口市秀英区南海大道 192 号海药工业园公司会议室 5、现场会议主持人：公司第十一届董事会董事长王建平 6、公司部分董事和高级管理人员现场或通过视频方式出席了本次股东会，北京大 成(海口)律师事务所见证律师对本次股东会进行见证，并出具法律意见书。 7、公司已于 2026 年 2 月 26 日在巨潮 ...

从资金流向上来看，当日互联网医疗板块主力资金净流出13.18亿元，游资资金净流入8.2亿元，散户资 金净流入4.98亿元。互联网医疗板块个股资金流向见下表： 证券之星消息，2月26日互联网医疗板块较上一交易日下跌0.67%，海南海药领跌。当日上证指数报收 于4146.63，下跌0.01%。深证成指报收于14503.79，上涨0.19%。互联网医疗板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

从资金流向上来看，当日医疗信息化板块主力资金净流出7.64亿元，游资资金净流入4.65亿元，散户资 金净流入2.99亿元。医疗信息化板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月26日医疗信息化板块较上一交易日下跌0.26%，海南海药领跌。当日上证指数报收 于4146.63，下跌0.01%。深证成指报收于14503.79，上涨0.19%。医疗信息化板块个股涨跌见下表： ...

Core Insights - Hainan Haiyao Co., Ltd. has achieved significant progress in its innovative drug development pipeline, with two new drugs reaching key clinical milestones, enhancing the company's competitive edge in the treatment of neurological and liver diseases [1] Group 1: Drug Development Progress - The drug Paenagabin, developed in collaboration with the Shanghai Institute of Materia Medica, has successfully completed Phase IIa clinical trials, showing promising results in treating focal epilepsy [2] - The Phase II clinical trial of the drug Fluofenidone, developed with Central South University, has met its primary research endpoints, indicating its potential in treating chronic hepatitis B-related liver fibrosis [4] Group 2: Clinical Trial Details - Paenagabin is a new generation KCNQ potassium channel agonist, targeting focal epilepsy that is resistant to existing treatments, with no similar products currently available globally [2][3] - The Phase II trial of Fluofenidone has established optimal dosing for reversing liver fibrosis and improving liver function, with safety profiles comparable to placebo [4][5] Group 3: Market Potential and Future Plans - There is a significant unmet clinical need in epilepsy treatment, with approximately 30% of patients not responding well to current therapies, positioning Paenagabin as a potential solution [3] - Fluofenidone has been recognized as a breakthrough therapy by the National Medical Products Administration, which may expedite its approval process [5] - Hainan Haiyao aims to expand its drug pipeline with a focus on multiple indications and targets, enhancing its research and development efforts to meet clinical demands [6][7]

Group 1 - The core point of the announcement is the approval of the proposal regarding the change of the commitment period for avoiding competition by the controlling shareholders, which will be submitted for shareholder approval [1][4][21] - The board meeting was held on February 25, 2026, with all 9 directors present, and the proposal received 6 votes in favor, 0 against, and 0 abstentions [3][21] - The independent directors held a special meeting and agreed to submit the proposal to the board, confirming compliance with relevant regulations and that it would not harm the interests of the company or its shareholders [2][22] Group 2 - The proposal to sign a financial service agreement with the financial company was also approved, which includes services such as deposits, settlements, and comprehensive credit [5][30] - The financial service agreement is set to be renewed for three years, with a maximum daily deposit balance of 1 billion RMB and a total credit limit of 1 billion RMB [30][34] - The independent directors reviewed the financial service agreement and found it beneficial for the company, ensuring it would not harm the interests of shareholders [60] Group 3 - The announcement regarding the change in the commitment period for avoiding competition states that the new commitment period will extend for two years from the original expiration date, ensuring compliance with regulations [11][17] - The original commitment made in July 2019 included maintaining independence and resolving competition issues within five years, which has now been extended due to complexities in resolving historical issues [11][19] - The company has assessed that there is minimal direct competition between itself and the related companies, as their products and market focuses differ significantly [14][16]

（编辑 丛可心） 证券日报网讯 2月25日，海南海药发布公告称，公司拟与新兴际华集团财务有限公司续签《金融服务协 议》，期限自2026年4月23日至2029年4月22日，协议有效期内公司及控股子公司在财务公司每日最高存 款结余不超过10亿元，财务公司向公司提供的综合授信余额最高不超过10亿元。 ...

Group 1 - Company Hainan Haiyao announced that its 31st meeting of the 11th board of directors was held on February 25, 2026, via communication voting [1] - The meeting reviewed the proposal regarding the convening of the first temporary shareholders' meeting in 2026 [1]

Core Viewpoint - Hainan Haiyao (000566.SZ) has received letters from Xinxing Jihua Group and Xinxing Jihua Pharmaceutical Holdings regarding the extension of the commitment period to resolve competition issues with Xinxing Lingyun Pharmaceutical Chemical Co., Ltd. and Tianjin Huajin Pharmaceutical Co., Ltd. for an additional two years from the original commitment expiration date [1] Group 1 - Hainan Haiyao announced the receipt of letters from Xinxing Jihua Group and Xinxing Jihua Pharmaceutical Holdings [1] - The letters pertain to the commitment to resolve competition issues related to Xinxing Lingyun and Tianjin Huajin Pharmaceutical [1] - The commitment period has been extended for two years from the original expiration date [1]

Group 1 - Hainan Haiyao (000566.SZ) announced the receipt of letters from Xinxing Jihua Group Co., Ltd. and Xinxing Jihua Pharmaceutical Holdings Co., Ltd. regarding the extension of the commitment period to resolve the competition issues [1] - The commitment to resolve the competition issues related to Xinxing Lingyun Pharmaceutical Chemical Co., Ltd. and Tianjin Huajin Pharmaceutical Co., Ltd. will be fulfilled within two years from the original commitment expiration date [1]